# Lisa A. Carey

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lisa-a-carey/

## Facts

| Field | Value |
| --- | --- |
| Citations | 54,266 |
| Field | Breast Cancer Treatment Studies |
| h-index | 105 |
| i10-index | 365 |
| Last Known Institution | University of North Carolina at Chapel Hill |
| OpenAlex ID | https://openalex.org/A5052268581 |
| ORCID iD | 0000-0003-2388-4649 |
| Works | 989 |

## Researcher papers

Showing 12 of 17.

- [Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study](https://scholariq.org/papers/race-breast-cancer-subtypes-and-survival-in-the-carolina-breast-cancer-study/)
- [The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes](https://scholariq.org/papers/the-triple-negative-paradox-primary-tumor-chemosensitivity-of-breast-cancer/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update](https://scholariq.org/papers/estrogen-and-progesterone-receptor-testing-in-breast-cancer-asco-cap-guideline/)
- [The molecular portraits of breast tumors are conserved across microarray platforms](https://scholariq.org/papers/the-molecular-portraits-of-breast-tumors-are-conserved-across-microarray/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)](https://scholariq.org/papers/impact-of-the-addition-of-carboplatin-and-or-bevacizumab-to-neoadjuvant-once-per/)
- [Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-endocrine-therapy-and-targeted-therapy-for-breast/)
- [Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?](https://scholariq.org/papers/molecular-classification-and-molecular-forecasting-of-breast-cancer-ready-for/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [University of North Carolina at Chapel Hill](https://scholariq.org/institutions/university-of-north-carolina-at-chapel-hill/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.